Amgen sees potential for Horizon to close by mid-December under court schedule
JHVEPhoto/iStock Editorial via Getty Images

Amgen (NASDAQ:AMGN) agreed not to close its $28 billion purchase of Horizon Therapeutics (NASDAQ:HZNP) before Oct. 31 or the second business day after the court rules on the Federal Trade Commission's request to block the deal.

On Friday, the Chicago court overseeing the case issued an order granting the revised stipulated temporary restraining order, according to an 8-K filing on Monday.

Horizon (HZNP) expects that its planned sale to Amgen (AMGN) can close by mid-December if a request for a preliminary injunction is denied by the federal court, according to the filing. 
Last month, U.S. District Judge John Kness set a hearing for Sept. 11 on the FTC's efforts to block the combination.


More on Horizon Therapeutics, Amgen

Anticompetitive Behavior At United Therapeutics, Regeneron, And The FTC
FTC Surprise Challenge Of Amgen's Acquisition Of Horizon Therapeutics
Amgen agrees not to close Horizon deal before Sept. 15 in court agreement with FTC